A $6 billion investment in Ozempic, Wegovy was announced by Novo Nordisk

Negelle Morris, Novo Nordisk's senior vice president and head of U.S. cardiometabolic sales, spoke exclusively with ABC News.

The blockbuster drug producer is Europe’s most valuable company — and its home country is feeling the effects